Xencor Inc (XNCR)

Nov 26, 2024, 4:01 PM EST - 7 weeks ago

Xencor to Participate at Upcoming Investor Conferences

Nov 22, 2024, 2:00 PM EST - 2 months ago

Xencor: Plamotamab NHL Data Leads To RA Program Advancement

Nov 6, 2024, 4:01 PM EST - 2 months ago

Xencor Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 7:00 AM EST - 2 months ago

Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease

Oct 10, 2024, 8:09 AM EDT - 3 months ago

Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases

Oct 4, 2024, 8:01 AM EDT - 3 months ago

Xencor Announces Upcoming Change to Board of Directors

Sep 12, 2024, 4:01 PM EDT - 4 months ago

Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 12, 2024, 8:16 AM EDT - 4 months ago

Xencor: Vudalimab Development Along With Hidden Gem Candidate

Sep 11, 2024, 6:31 AM EDT - 4 months ago

Xencor Announces Pricing of $175 Million Public Offering of Common Stock

Sep 10, 2024, 4:01 PM EDT - 4 months ago

Xencor Announces Proposed Public Offering of Common Stock

Sep 9, 2024, 7:31 AM EDT - 4 months ago

Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs

Sep 6, 2024, 8:01 AM EDT - 4 months ago

Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024

Aug 5, 2024, 4:01 PM EDT - 5 months ago

Xencor Reports Second Quarter 2024 Financial Results

Jun 13, 2024, 8:01 AM EDT - 7 months ago

Xencor Regains CD20 x CD3 Bispecific T-Cell Engager

May 9, 2024, 4:09 PM EDT - 9 months ago

Xencor Reports First Quarter 2024 Financial Results

Apr 9, 2024, 8:01 AM EDT - 10 months ago

Xencor Appoints Bart Cornelissen as Chief Financial Officer

Feb 28, 2024, 4:01 PM EST - 11 months ago

Xencor to Present at Upcoming Investor Conferences

Feb 28, 2024, 12:35 AM EST - 11 months ago

Xencor, Inc. (XNCR) Q4 2023 Earnings Call Transcript

Feb 27, 2024, 4:01 PM EST - 11 months ago

Xencor Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 20, 2024, 4:31 PM EST - 11 months ago

Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update

Jan 3, 2024, 4:01 PM EST - 1 year ago

Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024, 8:01 AM EST - 1 year ago

Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy

Dec 26, 2023, 12:18 PM EST - 1 year ago

20 favorite small-cap stocks for 2024 among Wall Street analysts

ARLO CPRX DGII DVAX GPRE HLX IRWD

Nov 21, 2023, 4:01 PM EST - 1 year ago

Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference

Nov 8, 2023, 8:29 AM EST - 1 year ago

Xencor, Inc. (XNCR) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:01 PM EST - 1 year ago

Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million

Nov 7, 2023, 4:01 PM EST - 1 year ago

Xencor Reports Third Quarter 2023 Financial Results

Nov 3, 2023, 12:01 PM EDT - 1 year ago

Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting

Oct 31, 2023, 4:01 PM EDT - 1 year ago

Xencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023

Oct 27, 2023, 11:56 AM EDT - 1 year ago

Xencor: Data In Early 2024 Could Bring Shareholder Value

Oct 26, 2023, 8:01 AM EDT - 1 year ago

Xencor Announces Planned Retirement of Chief Financial Officer John Kuch

Oct 20, 2023, 11:02 PM EDT - 1 year ago

Xencor: A Mid-Stage Clinical Company With Falling Losses

Sep 27, 2023, 9:01 AM EDT - 1 year ago

Xencor to Present Multiple Posters at the SITC Annual Meeting

Sep 19, 2023, 4:01 PM EDT - 1 year ago

Xencor Appoints Barbara J. Klencke, M.D.

Aug 6, 2023, 3:20 AM EDT - 1 year ago

Xencor, Inc. (XNCR) Q2 2023 Earnings Call Transcript

Aug 3, 2023, 4:01 PM EDT - 1 year ago

Xencor Reports Second Quarter 2023 Financial Results

Jul 27, 2023, 8:01 AM EDT - 1 year ago

Xencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023

May 30, 2023, 6:01 PM EDT - 1 year ago

Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress

May 8, 2023, 10:25 PM EDT - 1 year ago

Xencor, Inc. (XNCR) Q1 2023 Earnings Call Transcript

May 8, 2023, 4:01 PM EDT - 1 year ago

Xencor Reports First Quarter 2023 Financial Results

May 1, 2023, 4:01 PM EDT - 1 year ago

Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023

Apr 26, 2023, 8:01 AM EDT - 1 year ago

Xencor Appoints Nancy Valente, M.D., as Chief Development Officer

Apr 17, 2023, 1:31 PM EDT - 1 year ago

Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023

Mar 14, 2023, 4:31 PM EDT - 2 years ago

Xencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023

Feb 23, 2023, 11:11 PM EST - 2 years ago

Xencor, Inc. (XNCR) Q4 2022 Earnings Call Transcript

Feb 23, 2023, 4:01 PM EST - 2 years ago

Xencor Reports Fourth Quarter and Full Year 2022 Financial Results

Feb 16, 2023, 4:01 PM EST - 2 years ago

Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023

Feb 7, 2023, 4:01 PM EST - 2 years ago

Xencor to Present at the SVB Securities Global Biopharma Conference

Jan 9, 2023, 8:01 AM EST - 2 years ago

Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates

Jan 5, 2023, 6:30 AM EST - 2 years ago

Caris Life Sciences and Xencor Expand Target Discovery Collaboration for Novel XmAb® Antibody Drug Candidates